Panel IDs Hyperglycemia Management Options For Novartis’ Signifor
Executive Summary
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee suggests aggressive monitoring and limitations for who should take pasireotide, which the panel backed unanimously Nov. 7.